Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Tweed, Conor; Dawson, Rodney; A. Burger, Divan; Conradie, Almari; M. Crook, Angela; M. Mendel, Carl; Conradie, Francesca; H. Diacon, Andreas; Elias Ntinginya, Nyanda; E. Everitt, Daniel; Haraka, Frederick; Li, Mengchun; van Niekerk, C.H.; Okwera, Alphonse; Rassool, Mohammed; Reither, Klaus; Sebe, Modulakgotla; Staples, Suzanne; Variava, Ebrahim; Spigelman, Melvin

doi:10.1016/s2213-2600(19)30366-2

Public

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Published in The Lancet Respiratory Medicine • Nov 12, 2019

Authors:

Conor Tweed

Rodney Dawson

Divan A. Burger

Abstract

BackgroundNew anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquiline...

Subject

Pyrazinamide

Medicine

Bedaquiline

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!